Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
Development of Innovative Therapeutic Lung Cancer Drug Using AIMP2-DX2_Neomics
Korea Health Industry Development Institute (KHIDI) South Korea flag South Korea
Abstract ID:
Potent lung cancer suppressor associated to multiple-cancer signalling...
Contact Yong U Kim
Participants
You
Email me a copy of this message

1.  Potent lung cancer suppressor associated to multiple-cancer signaling


 


: Our target AIMP2 is related to a couple of major cancer pathways. AIMP2 enhances cell death extrinsically and intrinsically. Further AIMP2 suppresses cellular proliferation via beta-catenin and c-myc pathways. Targeting this multifunctional protein can protect the clinical trial from acquiring drug resistance. 


 


2.  Targeting cancer -specifically inducible oncogene


 


: We suppress a splicing variant induced in tumor region. Therefore we can efficiently avoid side effect on normal cells.


 


3.  Screening platform to optimize siRNA


 


: We should optimize siRNA to fit the lung cancer therapy and we developed a platform to screen siRNA. That techniques include monitoring transfection yield, calculating released cytokines and comparative method about siRNA stability.


 


4.  Expert delivery skill of siRNA to lung


 


: We have designed several delivery system and carrier to lung.


 


5.  Basic research infra to prove a value of novel therapeutic target


 


: We have studied the various functions of tRNA synthetases and the co-factors. Although now we are focusing on oncology, we have enough experiences with immunology and biochemistry. Moreover, because Dr. Kim’s Lab of Seoul National University also cooperate our researches, we can deal with several high techniques.  

FEATURED
Last Updated Jun 2016
Technology Type THERAPEUTIC
Phase of Development EARLY STAGE
GOVERNMENT INSTITUTE